Review
References
|
Abeer S (2012). Future medicine: Nanomedicine. JIMSA 25(3):187-192. |
|
|
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A (2018a). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-alzheimer drugs. Journal of Controlled Release 281:139-177. |
|
|
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Hamano N, Li SD, Chougule M, Shoyele SA, Gupta U, Ajazuddin, Alexander A (2018b). Recent advancements in the field of nanotechnology for the delivery of anti-alzheimer drug in the brain region. Expert opinion on drug delivery 15(6):589-617. |
|
|
Ahamed M (2011). Toxic response of nickel nanoparticles in human lung epithelial a549 cells. Toxicology in Vitro 25(4):930-936. |
|
|
Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, Rahman Z, Ahmad FJ, Storm G, Kok RJ (2013). Nanomedicines as cancer therapeutics: Current status. Current Cancer Drug Targets 13(4):362-378. |
|
|
Alexander A, Saraf S, Agrawal M, Patel R, Agrawal P, Khan J (2018). Amalgamation of stem cells with nanotechnology: A unique therapeutic approach. Current Stem Cell Research and Therapy. |
|
|
Antimisiaris SG, Mourtas S, Markoutsa E, Skouras A, Papadia K (2014). Nanoparticles for diagnosis and/or treatment of alzheimer's disease. In: Advanced healthcare materials. John Wiley & Sons, Inc., pp. 87-179. |
|
|
Arora P, Sindhu A, Dilbaghi N, Chaudhury A, Rajakumar G, Rahuman AA (2012). Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans. Journal of Cellular and Molecular Medicine 16(9):1991-2000. |
|
|
Aschengrau ASG (2008). Essentials of epidemiology in public health. MA: Jones and Bartlett Publishers. |
|
|
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016). Nanoparticle-based medicines: A review of fda-approved materials and clinical trials to date. Pharmaceutical Research 33(10):2373-2387. |
|
|
Bouck N, Stellmach V, Hsu SC (1996). How tumors become angiogenic. Advances in Cancer Research 69:135-174. |
|
|
Brand W, Noorlander CW, Giannakou C, De Jong WH, MW Kooi, MV Park, RJ Vandebriel, IE Bosselaers, JH Scholl, RE Geertsma (2017). Nanomedicinal products: A survey on specific toxicity and side effects. International Journal of Nanomedicine, 12:6107-6129. |
|
|
Cerrillo C, Barandika G, Igartua A, Areitioaurtena O, Mendoza G (2017). Key challenges for nanotechnology: Standardization of ecotoxicity testing. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis and Ecotoxicology Reviews 35(2):104-126. |
|
|
Chen D, Love KT, Chen Y, Eltoukhy AA, Kastrup C, Sahay G, Jeon A, Dong Y, Whitehead KA, Anderson DG (2012). Rapid discovery of potent sirna-containing lipid nanoparticles enabled by controlled microfluidic formulation. Journal of the American Chemical Society 134(16):6948-6951. |
|
|
Ciappellano SG, Tedesco E, Venturini M, Benetti F (2016). In vitro toxicity assessment of oral nanocarriers. Advanced drug delivery reviews 106(Pt B):381-401. |
|
|
Costa C, Brandao F, Bessa MJ, Costa S, Valdiglesias V, Kilic G, Fernandez-Bertolez N, Quaresma P, Pereira E, Pasaro E, Laffon B, Teixeira JP (2016). In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests. Journal of Applied Toxicology 36(3):361-372. |
|
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 7(1):11-20. |
|
|
Devatha CP, Jagadeesh K, Patil M (2018). Effect of green synthesized iron nanoparticles by azardirachta indica in different proportions on antibacterial activity. Environmental Nanotechnology, Monitoring and Management 9:85-94. |
|
|
Dhawan A, Sharma V (2010). Toxicity assessment of nanomaterials: Methods and challenges. Analytical and Bioanalytical Chemistry 398(2):589-605. |
|
|
Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE (2010). Ambiguities in applying traditional limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (London, England) 5(4):555-562. |
|
|
Dvir T, Timko BP, Brigham MD, Naik SR, Karajanagi SS, Levy O, Jin H, Parker KK, Langer R, Kohane DS (2011). Nanowired three-dimensional cardiac patches. Nature Nanotechnology 6(11):720-725. |
|
|
Escamilla-Rivera V, Uribe-Ramirez M, Gonzalez-Pozos S, Lozano O, Lucas S, De Vizcaya-Ruiz A (2016). Protein corona acts as a protective shield against fe3o4-peg inflammation and ros-induced toxicity in human macrophages. Toxicology Letters 240(1):172-184. |
|
|
Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine 9(1):1-14. |
|
|
Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B (2008). Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Archives of toxicology 82(3):151-157. |
|
|
Feng L, XR Qi, XJ Zhou, Y Maitani, Wang SC, Jiang Y, Nagai T (2006). |
|
|
Pharmaceutical and immunological evaluation of a single-dose hepatitis b vaccine using plga microspheres. Journal of controlled release: Official Journal of the Controlled Release Society 112(1):35-42. |
|
|
Han Y-g, Xu J, Li Z-g, Ren G-g, Z Yang (2012). In vitro toxicity of multi-walled carbon nanotubes in c6 rat glioma cells. NeuroToxicology 33(5):1128-1134. |
|
|
Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M (2016). Nanomedicines: From bench to bedside and beyond. The AAPS Journal 18(6):1373-1378. |
|
|
Hu Y, Fine DH, Tasciotti E, Bouamrani A, Ferrari M (2011). Nanodevices in diagnostics. Wiley interdisciplinary reviews. Nanomedicine and Nanobiotechnology 3(1):11-32. |
|
|
Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Ali B, Khalil AT, Kanwal S, Shah SA, Alam MM, Badshah H, Munir A (2018). Nanomedicines for developing cancer nanotherapeutics: From benchtop to bedside and beyond. Applied Microbiology and Biotechnology 102(22):9449-9470. |
|
|
Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, Langer R, Farokhzad OC (2008). Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano letters 8(9):2906-2912. |
|
|
Kaur IP, Kakkar V, Deol PK, Yadav M, Singh M Sharma I (2014). Issues and concerns in nanotech product development and its commercialization. Journal of controlled release Official Journal of the Controlled Release Society 193:51-62. |
|
|
Khan MI, Mohammad A, Patil G, Naqvi SA, Chauhan LK, Ahmad I (2012). Induction of ros, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. Biomaterials 33(5):1477-1488. |
|
|
Khare S, Alexander A, Amit N (2014). Biomedical applications of nanobiotechnology for drug design, delivery and diagnostics. Research Journal of Pharmacy and Technology 7(8):8. |
|
|
Khorasani AA, Weaver JL, Salvador-Morales C (2014). Closing the gap: Accelerating the translational process in nanomedicine by proposing standardized characterization techniques. International Journal of Nanomedicine 9:5729-5751. |
|
|
Kim Y, Lee CB, Ma M, Mulder WJ, Fayad ZA, Farokhzad OC, Langer R (2012). Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano letters, 12(7): 3587-3591. DOI 10.1021/nl301253v. |
|
|
Kroll, A., M.H. Pillukat, D. Hahn, J. Schnekenburger (2009). Current in vitro methods in nanoparticle risk assessment: Limitations and challenges. European Journal of Pharmaceutics and Biopharmaceutics, 72(2): 370-377. |
|
|
Kroll, A., M.H. Pillukat, D. Hahn, J. Schnekenburger (2012). Interference of engineered nanoparticles with in vitro toxicity assays. Archives of toxicology, 86(7): 1123-1136. DOI 10.1007/s00204-012-0837-z. |
|
|
Kumar H, Gothwal A, Khan I, Nakhate KT, Alexander A, Singh V, Gupta U (2017). Galactose-anchored gelatin nanoparticles for primaquine delivery and improved pharmacokinetics: A biodegradable and safe approach for effective antiplasmodial activity against p. Falciparum 3d7 and in vivo hepatocyte targeting. Molecular pharmaceutics, 14(10):3356-3369. |
|
|
Linkov I, Satterstrom FK, Corey LM (2008). Nanotoxicology and nanomedicine: Making hard decisions. Nanomedicine: Nanotechnology, Biology and Medicine 4(2):167-171. |
|
|
Liu H, Ma L, Zhao J, Liu J, Yan J, Ruan J, Hong F (2009). Biochemical toxicity of nano-anatase tio2 particles in mice. Biological trace element research 129(1-3):170-180. |
|
|
Lozano O, Laloy J, Alpan L, Mejia J, Rolin S, Toussaint O, Dogne JM, Lucas S, Masereel B (2012a). Effects of sic nanoparticles orally administered in a rat model: Biodistribution, toxicity and elemental composition changes in feces and organs. Toxicology and Applied Pharmacology 264(2):232-245. |
|
|
Lozano O, Mejia J, Masereel B, Toussaint O, Lison D, Lucas S (2012b). Development of a pixe analysis method for the determination of the biopersistence of sic and tic nanoparticles in rat lungs. Nanotoxicology 6(3):263-271. |
|
|
Lv H, Zhang S, Wang B, Cui S, Yan J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 114(1):100-109. |
|
|
Maniam G, Mai CW, Zulkefeli M, Dufes C, Tan DM, Fu JY (2018). Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Frontiers in Pharmacology 9:1358. |
|
|
Maynard AD, Warheit DB, Philbert MA (2011). The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicological Sciences 120(Suppl 1):S109-129. |
|
|
Mulhopt S, Diabate S (2018). Characterization of nanoparticle batch-to-batch variability. Nanomaterials 8(5):311. |
|
|
Oberdorster G (2010). Safety assessment for nanotechnology and nanomedicine: Concepts of nanotoxicology. Journal of Internal Medicine 267(1):89-105. |
|
|
Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit D, Yang H (2005). Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Particle and Fibre Toxicology 2:8. |
|
|
Oostingh GJ, Casals E, Italiani P, Colognato R, Stritzinger R, Ponti J, Pfaller T, Kohl Y, Ooms D, Favilli F, Leppens H, Lucchesi D, Rossi F, Nelissen I, Thielecke H, Puntes VF, Duschl A, Boraschi D (2011). Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Particle and Fibre Toxicology 8(1):8. |
|
|
Park EJ, Lee GH, Shim HW, Kim JH, Cho MH, Kim DW (2014). Comparison of toxicity of different nanorod-type tio2 polymorphs in vivo and in vitro. Journal of applied toxicology. Journal of AT 34(4):357-366. |
|
|
Pautler M, Brenner S (2010). Nanomedicine: Promises and challenges for the future of public health. International Journal of Nanomedicine 5:803-809. |
|
|
Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010). Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. Journal of Autoimmunity 34(3):J226-233. |
|
|
Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S (2018). Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomedicine and Pharmacotherapy 107:447-463. |
|
|
Resnik DB, Tinkle SS (2007). Ethical issues in clinical trials involving nanomedicine. Contemporary Clinical Trials 28(4):433-441. |
|
|
Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R (2011). Synthesis of size-tunable polymeric nanoparticles enabled by 3d hydrodynamic flow focusing in single-layer microchannels. Advanced materials (Deerfield Beach, Fla.). 23(12):H79-83. |
|
|
Saraf S, Gupta A, Alexander A, Khan J, Jangde M, Saraf S (2015). Advancements and avenues in nanophytomedicines for better pharmacological responses. Journal of Nanoscience and Nanotechnology 15(6):4070-4079. |
|
|
Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature reviews. Cancer 17(1):20-37. |
|
|
Spagnou S, Miller AD, Keller M (2004). Lipidic carriers of sirna: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43(42):13348-13356. |
|
|
Tran S, DeGiovanni PJ, Piel B, Rai P (2017). Cancer nanomedicine: A review of recent success in drug delivery. Clinical and Translational Medicine 6(1):44. |
|
|
Ventola CL (2012). The nanomedicine revolution: Part 1: Emerging concepts. Pharmacy and Therapeutics 37(9):512-525. |
|
|
Verma C, Janghel A, Deo S, Raut P, Bhosle D, Kumar SS, Agrawal M, Amit N, Sharma M, Giri T (2015). A comprehensive advancement on nanomedicines along with its various biomedical applications. Research Journal of Pharmacy and Technology 8(7):945-957. |
|
|
Wei A, Mehtala JG, Patri AK (2012). Challenges and opportunities in the advancement of nanomedicines. Journal of Controlled Release 164(2):236-246. |
|
|
Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M, Zhao Y (2015). Safety of nanoparticles in medicine. Current Drug Targets 16(14):1671-1681. |
|
|
Xu J, Xu P, Li Z, Huang J, Yang Z (2012). Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in c6 cells. Journal of Biomedical Materials Research Part A 100(3):738-745. |
|
|
Zhang X, Li W, Yang Z (2015). Toxicology of nanosized titanium dioxide: An update. Archives of Toxicology 89(12):2207-2217. |
|
Copyright © 2022 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
